Selina M. Luger

faculty photo
Professor of Medicine at the Hospital of the University of Pennsylvania
Attending Physician , Hospital of the University of Pennsylvania
Member , Abramson Cancer Center, University of Pennsylvania
Director, Outpatient Practice, Stem Cell Transplant & Hematological Malignancies, Hospital of the University of Pennsylvania
Director, Leukemia Program, Abramson Cancer Center, Perelman School of Medicine
Chair,Hematology-Oncology Epic Governance, Perelman School of Medicine, University of Pennsylvania
Member, Epic Operations Committee, Hospital of the University of Pennsylvania
Board Member, Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Perelman Center 2 West
34th and Civic Center Blvd
Philadelphia, PA 19104
Office: 2156141847
Fax: 2156624064
A.B. (Biochemistry)
Harvard University, 1982.
M.D.CM (Medicine)
McGill University, 1987.
Permanent link

Description of Research Expertise

Leukemia, myelodysplastic syndrome, myeloproliferative disorders

Description of Itmat Expertise

Dr. Luger conducts translational research in leukemia, MDS and other hematologic malignancies.

Selected Publications

Reshef Ran, Hexner Elizabeth O, Loren Alison W, Frey Noelle V, Stadtmauer Edward A, Luger Selina M, Mangan James K, Gill Saar I, Vassilev Pavel, Lafferty Kathryn A, Smith Jacqueline, Van Deerlin Vivianna M, Mick Rosemarie, Porter David L: Early Donor Chimerism Levels Predict Relapse and Survival after Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation Jul 2014.

Fielding Adele K, Rowe Jacob M, Buck Georgina, Foroni Letizia, Gerrard Gareth, Litzow Mark R, Lazarus Hillard, Luger Selina M, Marks David I, McMillan Andrew K, Moorman Anthony V, Patel Bella, Paietta Elisabeth, Tallman Martin S, Goldstone Anthony H: UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood 123(6): 843-50, Feb 2014.

Hexner Elizabeth, Roboz Gail, Hoffman Ron, Luger Selina, Mascarenhas John, Carroll Martin, Clementi Regina, Bensen-Kennedy Debra, Moliterno Alison: Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation. British journal of haematology 164(1): 83-93, Jan 2014.

Landsburg, Daniel J. Stadtmauer, Edward. Loren, Alison. Goldstein, Steven. Frey, Noelle. Nasta, Sunita D. Porter, David L. Tsai, Donald E. Perl, Alexander E. Hexner, Elizabeth O. Luger, Selina.: Receipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens. American Journal of Hematology 88(8): 657-60, Aug 2013.

Kumar Anita J, Hexner Elizabeth O, Frey Noelle V, Luger Selina M, Loren Alison W, Reshef Ran, Boyer Jean, Smith Jacqueline, Stadtmauer Edward A, Levine Bruce L, June Carl H, Porter David L, Goldstein Steven C: Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 19(7): 1094-101, Jul 2013.

DiNardo, Courtney D. Propert, Kathleen J. Loren, Alison W. Paietta, Elisabeth. Sun, Zhuoxin. Levine, Ross L. Straley, Kimberly S. Yen, Katharine. Patel, Jay P. Agresta, Samuel. Abdel-Wahab, Omar. Perl, Alexander E. Litzow, Mark R. Rowe, Jacob M. Lazarus, Hillard M. Fernandez, Hugo F. Margolis, David J. Tallman, Martin S. Luger, Selina M. Carroll, Martin.: Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood 121(24): 4917-24, Jun 13 2013.

Gojo Ivana, Perl Alexander, Luger Selina, Baer Maria R, Norsworthy Kelly J, Bauer Kenneth S, Tidwell Michael, Fleckinger Stephanie, Carroll Martin, Sausville Edward A: Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome. Investigational new drugs 31(5): 1217-27, Feb 2013.

Dinardo Courtney D, Ogdie Alexis, Hexner Elizabeth O, Frey Noelle V, Loren Alison W, Luger Selina M: Characteristics and outcome of acute myeloid leukemia in patients with a prior history of autoimmune disease. Leukemia & lymphoma 54(6): 1235-41, Feb 2013.

Marks David I, Moorman Anthony V, Chilton Lucy, Paietta Elisabeth, Enshaie Amir, De Wald Gordon, Harrison Christine, Fielding Adele K, Foroni Letizia, Goldstone Anthony H, Litzow Mark R, Luger Selina M, McMillan Andrew K, Racevskis Janis, Rowe Jacob M, Tallman Martin S, Wiernik Peter, Lazarus Hillard M: The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated on UKALLXII/ECOG2993. Haematologica 98(6): 945-52, Jan 2013.

Diab Adi, Zickl Lynette, Abdel-Wahab Omar, Jhanwar Suresh, Gulam Manjit A, Panageas Katherine S, Patel Jay P, Jurcic Joseph, Maslak Peter, Paietta Elisabeth, Mangan James K, Carroll Martin, Fernandez Hugo F, Teruya-Feldstein Julie, Luger Selina M, Douer Dan, Litzow Mark R, Lazarus Hillard M, Rowe Jacob M, Levine Ross L, Tallman Martin S: Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis. Leukemia research 37(1): 32-6, Jan 2013.

back to top
Last updated: 09/16/2014
The Trustees of the University of Pennsylvania